CN114502543A - 靶向蛋白化合物、其药物组合物及治疗应用 - Google Patents

靶向蛋白化合物、其药物组合物及治疗应用 Download PDF

Info

Publication number
CN114502543A
CN114502543A CN202080052899.5A CN202080052899A CN114502543A CN 114502543 A CN114502543 A CN 114502543A CN 202080052899 A CN202080052899 A CN 202080052899A CN 114502543 A CN114502543 A CN 114502543A
Authority
CN
China
Prior art keywords
methyl
dioxopiperidin
optionally substituted
oxo
pyrrol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080052899.5A
Other languages
English (en)
Chinese (zh)
Inventor
凯尔·W·H·程
保罗·E·艾德曼
方黎
大卫·艾伦·赫克特
阿帕瑞吉塔·荷思可特·克瑞西亚
伊梅尔达·朗姆
法兰克·默库里奥
罗伯特·沙利文
爱德华多·托雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayorsrix Co
Original Assignee
Bayorsrix Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayorsrix Co filed Critical Bayorsrix Co
Publication of CN114502543A publication Critical patent/CN114502543A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN202080052899.5A 2019-05-24 2020-05-22 靶向蛋白化合物、其药物组合物及治疗应用 Pending CN114502543A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962852844P 2019-05-24 2019-05-24
US62/852844 2019-05-24
PCT/US2020/034264 WO2020242960A1 (en) 2019-05-24 2020-05-22 Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications

Publications (1)

Publication Number Publication Date
CN114502543A true CN114502543A (zh) 2022-05-13

Family

ID=71092611

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080052899.5A Pending CN114502543A (zh) 2019-05-24 2020-05-22 靶向蛋白化合物、其药物组合物及治疗应用

Country Status (14)

Country Link
US (2) US11345712B2 (cg-RX-API-DMAC7.html)
EP (1) EP3976623A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022533260A (cg-RX-API-DMAC7.html)
KR (1) KR20220023343A (cg-RX-API-DMAC7.html)
CN (1) CN114502543A (cg-RX-API-DMAC7.html)
AU (1) AU2020283744A1 (cg-RX-API-DMAC7.html)
CA (1) CA3140078C (cg-RX-API-DMAC7.html)
EA (1) EA202192910A1 (cg-RX-API-DMAC7.html)
IL (1) IL288204A (cg-RX-API-DMAC7.html)
MX (1) MX2021014345A (cg-RX-API-DMAC7.html)
SG (1) SG11202112355VA (cg-RX-API-DMAC7.html)
TW (1) TW202110818A (cg-RX-API-DMAC7.html)
WO (1) WO2020242960A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202109124B (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111247138A (zh) * 2017-08-25 2020-06-05 拜欧赛里克斯公司 醚化合物和其用途
CN115636811A (zh) * 2022-08-17 2023-01-24 成都分迪药业有限公司 异吲哚啉苄胺衍生物的合成方法
WO2024222918A1 (zh) * 2023-04-28 2024-10-31 中国药科大学 一种苯并六元杂环类gspt1蛋白降解剂及其应用
CN121219280A (zh) * 2023-09-26 2025-12-26 映恩生物制药(苏州)有限公司 哌啶二酮类化合物、其制备方法和用途
WO2026098548A1 (zh) * 2024-11-07 2026-05-15 四川科伦博泰生物医药股份有限公司 蛋白降解剂、其药物组合物及其用途和方法

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293481A (en) * 2019-12-06 2022-08-01 Celgene Corp Processes for the preparation of 2-(4-chlorophenyl)-n-((2-(2,6-dioxypyridin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
AU2020398965A1 (en) * 2019-12-12 2022-06-30 Biotheryx, Inc. PDE4 inhibitors, pharmaceutical compositions, and therapeutic applications
JP7871189B2 (ja) * 2019-12-17 2026-06-08 オリオニス バイオサイエンシズ,インコーポレイテッド タンパク質の動員および/または分解を調節する化合物
US20240025863A1 (en) 2020-09-16 2024-01-25 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
CN122562781A (zh) * 2020-10-07 2026-08-14 上海睿跃生物科技有限公司 治疗癌症的化合物和方法
TW202231269A (zh) 2020-10-23 2022-08-16 美商拜歐斯瑞克斯公司 Kras蛋白降解劑、其醫藥組合物及其治療應用
US20240124418A1 (en) 2020-12-14 2024-04-18 Biotheryx, Inc. Pde4 degraders, pharmaceutical compositions, and therapeutic applications
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物
EP4320125A1 (en) * 2021-04-05 2024-02-14 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
AU2022289605B2 (en) * 2021-06-08 2024-12-19 Hangzhou Glubio Pharmaceutical Co., Ltd. Isoindolinone compounds, and uses thereof
CN117440948A (zh) * 2021-06-28 2024-01-23 成都分迪药业有限公司 酰胺类化合物及其用途
WO2023001028A1 (zh) * 2021-07-19 2023-01-26 南京明德新药研发有限公司 杂芳-3-哌啶二酮类化合物及其应用
WO2023069708A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and uses thereof
WO2023069731A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
WO2023070120A1 (en) * 2021-10-22 2023-04-27 Biotheryx, Inc. Ketoamides for treating malignancy
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
US20240124412A1 (en) * 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
US12662467B2 (en) 2022-04-18 2026-06-23 BioThery X, Inc. Isoindolinones, pharmaceutical compositions, and therapeutic applications
CN114835680A (zh) * 2022-04-29 2022-08-02 成都分迪药业有限公司 卤素取代异吲哚啉化合物及其应用
JP2025522795A (ja) * 2022-06-27 2025-07-17 ピン セラピューティクス、インコーポレイテッド カゼインキナーゼ1アルファを分解するための化合物及び方法
JP2025531869A (ja) * 2022-09-09 2025-09-25 イノヴォ セラピューティクス、インコーポレイテッド CK1αおよびDUAL CK1α/GSPT1分解化合物
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2024167423A1 (en) * 2023-02-07 2024-08-15 Captor Therapeutics S.A. Gspt1 degrader compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US20170197933A1 (en) * 2016-01-08 2017-07-13 Celgene Corporation Antiproliferative compounds, and their pharmaceutical compositions and uses
CN108069959A (zh) * 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用
US20180170948A1 (en) * 2016-12-21 2018-06-21 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5469604B2 (ja) * 2007-09-19 2014-04-16 4エスツェー アクチェンゲゼルシャフト 新規テトラヒドロ融合ピリジン
WO2017201069A1 (en) * 2016-05-18 2017-11-23 Biotheryx, Inc. Oxoindoline derivatives as protein function modulators
KR101825065B1 (ko) * 2016-05-24 2018-02-05 한국화학연구원 Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2018169777A1 (en) 2017-03-14 2018-09-20 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
CN108929307A (zh) * 2017-05-22 2018-12-04 苏州偶领生物医药有限公司 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途
SG11202104495YA (en) * 2018-04-26 2021-05-28 Aurigene Discovery Tech Ltd Pyridazine derivatives as smarca2/4 degraders
US10905684B2 (en) 2018-06-13 2021-02-02 Biotheryx, Inc. Aminoamide compounds
WO2020023782A1 (en) * 2018-07-27 2020-01-30 Biotheryx, Inc. Bifunctional compounds as cdk modulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US20170197933A1 (en) * 2016-01-08 2017-07-13 Celgene Corporation Antiproliferative compounds, and their pharmaceutical compositions and uses
CN108069959A (zh) * 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用
US20180170948A1 (en) * 2016-12-21 2018-06-21 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111247138A (zh) * 2017-08-25 2020-06-05 拜欧赛里克斯公司 醚化合物和其用途
CN115636811A (zh) * 2022-08-17 2023-01-24 成都分迪药业有限公司 异吲哚啉苄胺衍生物的合成方法
WO2024222918A1 (zh) * 2023-04-28 2024-10-31 中国药科大学 一种苯并六元杂环类gspt1蛋白降解剂及其应用
CN121219280A (zh) * 2023-09-26 2025-12-26 映恩生物制药(苏州)有限公司 哌啶二酮类化合物、其制备方法和用途
WO2026098548A1 (zh) * 2024-11-07 2026-05-15 四川科伦博泰生物医药股份有限公司 蛋白降解剂、其药物组合物及其用途和方法

Also Published As

Publication number Publication date
US20220298172A1 (en) 2022-09-22
MX2021014345A (es) 2022-01-06
KR20220023343A (ko) 2022-03-02
US20200369679A1 (en) 2020-11-26
CA3140078A1 (en) 2020-12-03
WO2020242960A1 (en) 2020-12-03
JP2022533260A (ja) 2022-07-21
CA3140078C (en) 2023-11-28
EP3976623A1 (en) 2022-04-06
IL288204A (en) 2022-01-01
ZA202109124B (en) 2023-10-25
TW202110818A (zh) 2021-03-16
AU2020283744A1 (en) 2021-12-09
SG11202112355VA (en) 2021-12-30
EA202192910A1 (ru) 2022-03-18
US11345712B2 (en) 2022-05-31

Similar Documents

Publication Publication Date Title
US11345712B2 (en) Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications
JP7050879B2 (ja) ピラゾール化合物ならびにこの化合物を作製および使用するための方法
JP6882299B2 (ja) 多環式tlr7/8アンタゴニスト及び免疫障害の治療におけるそれらの使用
JP5392917B2 (ja) Npyy5受容体拮抗作用を有するアミン誘導体
CN102300862B (zh) 用作atr激酶抑制剂的化合物
TW202229285A (zh) Kras g12d抑制劑
EP2681215B1 (en) Serine/threonine kinase inhibitors
EP2976341B1 (en) Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
KR20190093205A (ko) 단백질 표적화에 사용하기 위한 티에노피롤 유도체, 조성물, 방법 및 이의 용도
BRPI0407827B1 (pt) Compostos de aminoeteroarila como inibidores de proteína cinase e respectivos usos
TW201546058A (zh) 哌啶基吲哚衍生物補體因子b抑制劑及其用途
JPWO2009054434A1 (ja) Npyy5受容体拮抗作用を有するアミン誘導体およびその用途
CN115768773A (zh) 作为ent抑制剂用于治疗癌症的大环二胺衍生物以及其与腺苷受体拮抗剂的组合
CN111163766A (zh) Ahr抑制剂和其用途
JP2018510135A (ja) RORγT阻害剤としての置換ピラゾール化合物及びその使用
CN115427394A (zh) 用于调节nr2f6的杂环化合物
TW202417449A (zh) Cdk2抑制劑及使用彼等之方法
CN106458987B (zh) 用于治疗疾病诸如糖尿病的吡咯烷gpr40调节剂
CN117751099A (zh) 酰胺类化合物及其应用
CN101479238B (zh) 具有npyy5受体拮抗活性的胺衍生物
JP2010270114A (ja) Npyy5受容体拮抗作用を有するアミン誘導体およびその用途
KR20250057795A (ko) 단백질 포스파타제 2a(pp2a) 조절제로서 사용하기 위한 방향족 화합물
JP2024540428A (ja) 分解剤及びその使用
HK40063935A (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
EA047011B1 (ru) Производные сульфонилмочевины в качестве модуляторов nlrp3 инфламмасомы

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220513